Ian Tannock
Overview
Explore the profile of Ian Tannock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meirson T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, Markel G, Neiman V, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2455630.
PMID: 39841472
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone...
2.
James N, Tannock I, Ndow J, Feng F, Gillessen S, Ali S, et al.
Lancet
. 2024 Apr;
403(10437):1683-1722.
PMID: 38583453
No abstract available.
3.
Chan A, Cheng I, Wang C, Tan C, Toh Y, Ng D, et al.
Cancer Med
. 2022 Oct;
12(4):4821-4831.
PMID: 36221816
Background: There is little information about cancer-related cognitive impairment (CRCI) in adolescent and young adults (AYA, 15-39 years old) due to its rare incidence. Here, we present the pre-treatment (before...
4.
Ranganathan P, Chinnaswamy G, Sengar M, Gadgil D, Thiagarajan S, Bhargava B, et al.
Lancet Oncol
. 2021 Jul;
22(8):e369-e376.
PMID: 34216541
Low-income and middle-income countries (LMICs) have a disproportionately high burden of cancer and cancer mortality. The unique barriers to optimum cancer care in these regions necessitate context-specific research. The conduct...
5.
Tannock I, Presley C, Saltz L
Am Soc Clin Oncol Educ Book
. 2019 May;
39:122-131.
PMID: 31099632
Registration of new anticancer drugs is decided too often not by their clinical value but by a p value. Approval is granted if the difference in an acceptable time-to-event outcome...
6.
Kimmelman J, Tannock I
Nat Rev Clin Oncol
. 2018 Apr;
15(6):341-342.
PMID: 29674669
No abstract available.
7.
Hahn E, Ariely D, Tannock I, Fyles A, Corn B
Lancet Oncol
. 2018 Apr;
19(4):447-448.
PMID: 29611516
No abstract available.
8.
Wallis C, Cheung D, Klotz L, Chalasani V, Leao R, Garisto J, et al.
Can Urol Assoc J
. 2018 Jan;
12(2):E59-E63.
PMID: 29381460
Introduction: We aimed to determine the personal practices of urologists, radiation oncologists, and medical oncologists regarding prostate cancer screening and treatment using the physician surrogate method, which seeks to identify...
9.
Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R, et al.
Eur Urol
. 2017 Jun;
73(2):178-211.
PMID: 28655541
Background: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or...
10.
Zhang S, Liang F, Tannock I
BMC Cancer
. 2016 Jul;
16:392.
PMID: 27377548
Background: Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) were released in 2003 and have been used widely to report toxicity in publications or presentations describing cancer clinical...